Ascendiant Capital Markets Issues Positive Forecast for NRx Pharmaceuticals (NASDAQ:NRXP) Stock Price

NRx Pharmaceuticals (NASDAQ:NRXP) had its target price boosted by investment analysts at Ascendiant Capital Markets from $45.00 to $46.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Other analysts have also recently issued reports about the company. BTIG Research started coverage on NRx Pharmaceuticals in a research report on Wednesday, April 2nd. They issued a “buy” rating and a $18.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $19.00 price target on shares of NRx Pharmaceuticals in a report on Thursday, March 20th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $31.00 price objective on shares of NRx Pharmaceuticals in a report on Monday, March 31st. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $28.50.

NRx Pharmaceuticals Stock Performance

NRXP stock opened at $2.10 on Tuesday. NRx Pharmaceuticals has a 1 year low of $1.10 and a 1 year high of $6.01. The stock has a market capitalization of $35.52 million, a price-to-earnings ratio of -0.98 and a beta of 1.41. The stock’s fifty day moving average is $2.05 and its two-hundred day moving average is $2.09.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings data on Friday, March 14th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.10). As a group, analysts predict that NRx Pharmaceuticals will post -1.75 EPS for the current fiscal year.

Institutional Trading of NRx Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of NRXP. Sassicaia Capital Advisers LLC purchased a new position in shares of NRx Pharmaceuticals in the fourth quarter worth approximately $33,000. Squarepoint Ops LLC acquired a new position in NRx Pharmaceuticals in the 4th quarter worth approximately $56,000. Millennium Management LLC purchased a new position in NRx Pharmaceuticals during the 4th quarter worth approximately $61,000. Anson Funds Management LP raised its stake in NRx Pharmaceuticals by 30.3% during the 4th quarter. Anson Funds Management LP now owns 185,660 shares of the company’s stock valued at $408,000 after purchasing an additional 43,135 shares during the period. Finally, AdvisorShares Investments LLC lifted its holdings in shares of NRx Pharmaceuticals by 138.5% in the fourth quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock valued at $683,000 after purchasing an additional 180,229 shares in the last quarter. Institutional investors and hedge funds own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.